Pfizer Acquires Anacor, Reviving M&A Bets in Biotech Sector, ETFs

Revitalizing the merger and acquisition outlook for biotech sector exchange traded funds, Pfizer (NYSE: PFE) announced it will buy biopharma company Anacor Pharmaceuticals (NasdaqGS: ANAC). Pfizer paid a 55% premium to Anacor’s closing price last Friday for $5.2 billion, gaining control over...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.